The following table is a representation of predicted clinical outcomes for patients treated with agents found active in the laboratory using the EVA-PCD functional profile.
With performance characteristics borrowed from the studies described earlier, these analyses have a sensitivity of 78.4% and specificity of 90.1%.
This column provides expected clinical response rate based on current literature reported response rates (pre-test expectation).
These range from a 10% expected response rate for malignancies such as melanoma or renal cell carcinoma, up to 70% expected response rate for diseases such as untreated ovarian cancer or breast cancer.
Since the earliest introduction of cytotonic chemotherapy, investigators have pursued laboratory techniques designed to match patients to available drugs.
Most of the work, published in the 1980s, reflected the prevailing view of cancer as a disease of dysregulated cell proliferation.